A universal flu vaccine is the holy grail of influenza immunizations. The yearly process of making educated guesses about the upcoming flu season would end, replaced by a vaccine for many of the strains. It is a massive challenge, but one that Sanofi and others have taken up.
In pandemic flu preparation, a lot of focus is placed on protecting against the specific viral strain. Yet analysis of the 1918 pandemic shows secondary bacterial pneumonia directly caused many of the deaths. This brings Pfizer's Prevnar 13 into play, and the Big Pharma is talking up its role.
The Department of Health and Human Services last year anted up $400 million as part of an ambitious plan to expand vaccine manufacturing in the U.S. which it could tap in case of a pandemic. One leg of a three-legged stool on which that plan sits is about to be built.
In response to concerns about biodefense, the Department of Health and Human Services is helping GlaxoSmithKline and Texas A&M build a $91 million vaccine production plant.
Just as news channels use computer models to forecast weather, data on weather conditions might also be helpful in predicting disease outbreaks.
CSL will manufacture and store antigens that can be used against influenza strains with pandemic potential.
Australia-based vaccine maker CSL Biotherapies, which has had to deal with some quality issues raised by the FDA, has been selected by the U.S. government to further strengthen the country's supply of pre-pandemic and pandemic vaccine antigens in case of an influenza outbreak.
A lab-engineered bird flu strain spread easily among mammals, and the Nature article that reports the findings remains part of a hot debate in science about whether to guard details from research that could be used in the wrong hands to do harm.
A joint effort by government and industry has begotten a nearly $1 billion cell-culture flu vaccine manufacturing facility. Novartis ( $NVS ) and the U.S. Department of Health and Human Services
To improve its ability to cope with epidemic emergencies, China says it will spend $1.45 billion to develop a national vaccine provision system. The goal is to create a system that can supply